Meet the new King of the PBS

MSD's monoclonal antibody, Keytruda, has been stalking the top spot of PBS reimbursements for more than a year, and in April it took the lead.

Last month Keytruda earned $52,220,013 in pre-rebate reimbursements on the R/PBS, edging out Vertex's cystic fibrosis drug Trikafta, which pulled in $50,937,420.

It's been a long road for Keytruda, which spent years playing second fiddle to Bayer's eye drug Eylea, only to be overtaken by MSD's antiviral Lagevrio when competition ate into Eylea's earnings, and then Trikafta when the Covid demand fell.